Tranquis Therapeutics Inc. has announced preclinical data on the antiaging effects of TQS-168, a small-molecule modulator of PGC-1alpha (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha).

Armed with intellectual property generated in the lab of Edgar Engleman at Stanford University, Tranquis Therapeutics Inc. has emerged from stealth mode through a $30 million series A round.